Research notes

1Q26 delivered a step-change in commercial execution, with 41 implants (+128% q/q) and preliminary revenue of US$2.25-2.36m, materially ahead of prior run-rate. Importantly, growth is being driven by repeat usage, not just new site additions, with the majority of 1Q implants coming from existing centres, supporting confidence in utilisation and scalability. Leading indicators remain strong, with 37 purchasing agreements, 55 physicians trained, and double-digit physician training demand, alongside with emerging multi-site IDN/GPO contracts. Commercial bottleneck remains execution (sales capacity and contracting), not demand, with patient backlogs building and physician engagement “very high”. We make no changes to CY26-28 forecasts or A$2.47 DCF-based valuation. BUY.

ORA’s trading update highlighted challenging operating conditions at Saverglass stemming from the ongoing conflict in the Middle East. The conflict has affected operations both directly and indirectly: directly through the effective closure of ORA’s Ras Al Khaimah (RAK) facility in the UAE, and indirectly through lower spirits volumes and an adverse product-mix shift, which have weighed on earnings. We adjust FY26/27/28F underlying EBIT by -8%/-11%/-10%. Our target price declines to $1.55 (from $2.30) and we maintain our HOLD rating. Given the ongoing uncertainty surrounding the conflict in the Middle East, visibility on the timing of a potential restart at the RAK facility remains limited. In addition, global consumer confidence and spirits demand have already been negatively affected by the conflict and may remain subdued for some time, even in the event of a near-term resolution. Given this uncertainty, we believe it is prudent to await further updates before reassessing our view. Within the Packaging sector, our preference remains Amcor (AMC, BUY, $76.00 TP).

Diageo is a global leader in premium alcoholic beverages and the number one player in the international spirits category. The company owns nine of the world’s top 30 spirits brands and operates across multiple categories including Scotch whisky, vodka, rum, gin, tequila, beer, ready-to-drink (RTD) products and liqueurs. Its portfolio features iconic names such as Johnnie Walker, Crown Royal, Buchanan’s, Windsor and Bushmills whiskies, Smirnoff, Cîroc and Ketel One vodkas, Captain Morgan rum, Baileys liqueur, Don Julio tequila, Tanqueray gin and Guinness stout.

SIG is a leading healthcare wholesaler, distributor and retail pharmacy franchisor with operations in Australia, NZ, Ireland and the UAE. We are forecasting ~20% EBIT growth p.a. over the next few years driven by strong LFL sales growth, store rollout (domestically and internationally), operating efficiencies and $100m p.a. synergies by FY29. Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.

6K Additive (6KA) is a US-based advanced materials company that upcycles metal waste into engineered feedstock, producing high-value powders and alloys for aerospace, defence, medical, energy, and industrial applications. The company delivered 4Q25 revenue of US$5.6m (representing a run-rate of ~US$22.4m pa) with over 100 active customers including ABB, Boeing and Ford. 6KA has a potential sales pipeline of ~US$250m pa and plans to use proceeds from its recent IPO (Dec-25) to consolidate and scale its operations in the US. This will result in a 5x increase in powder production capacity (from 200mt to 1,000mt) and deliver significant margin improvement and production efficiency. We initiate coverage on 6KA with a SPECULATIVE BUY rating and a target price of $1.30. Backed by proven technology, a closed-loop model, and broad customer validation, we believe the company is well-positioned to benefit from strong demand in metal additive manufacturing and US government initiatives to reshore the sourcing and processing of critical minerals. Trading on 3.7x FY27F (Jun Y/E equivalent) EV/Revenue versus a domestic peer median of 9.5x, we view 6KA’s valuation as relatively attractive - though suited to more assertive investors.

MFG has given an end-to-March 2026 quarterly FUM update. FUM (A$37.5bn) was down 6% for the quarter due to a combination of outflows across most funds and market movements. Overall this was a softer quarter at the headline level, albeit some impacts from market volatility are unsurprising. We downgrade our MFG FY26F/FY27F EPS by -1%/-8% due to slightly weaker FUM assumptions and also applying more conservatism to our future Barrenjoey earnings forecasts. Our PT falls to A$11.99 (from A$12.43). Whilst MFG’s Investment Management performance remains patchy, we think the Barrenjoey merger fundamentally changes MFG’s overall outlook, strengthening the business and providing additional pathways for growth. MFG also retains a strong balance sheet (~A$650m of liquidity, post deal). BUY maintained.

We initiate with a BUY rating and A$4.85 target, implying ~20% total return (15% capital + ~5% fully franked yield). DRR offers a rare capital-light exposure to tier-1 iron ore via a 1.232% Gross Revenue Royalty over BHP’s Mining Area C (a 45yr+ mine life asset with near-zero operating risk for the royalty holder) which delivers a 93% EBITDA margin. The Trident acquisition (Sep-24) added Thacker Pass, a 1.05% Gross Royalty Revenue (GRR) over a global-scale lithium deposit (85yr mine life, General Motors-backed). This provides genuine battery metals optionality worth A$0.40/share risked, diversifying the revenue base beyond iron ore. DRR trades at 9.7x FY27F EV/EBITDA, a 32-46% discount to global royalty peers (Franco-Nevada 19x, Wheaton 18x) that we believe is excessive given robust earnings platform, path to net cash, and emerging capital return optionality.

Many Peaks Minerals (ASX:MPK) is exploring the Ferke Gold Project (76.5%) in Cote d’Ivoire. Our modelling suggests the Ouarigue South system has already exceeded 1Moz Au ahead of an imminent Maiden MRE. At Ferke, our thesis is driven by geometry and early-stage economics rather than in-situ ounces. Broad widths deliver favourable geometry supporting low strip ratios and unit costs, meaning scale doesn’t need to be excessive to deliver robust economics. Our mining scenario outlines an initial 7.5-year operation producing ~110kozpa at an AISC of ~A$2,525/oz, with underground and regional potential providing a clear runway for mine life extensions and project scale growth. We initiate with a SPECULATIVE BUY recommendation and price target of A$1.92ps (assuming an effective 76.5% ownership, incl. government free carry).

GYG's Q3 FY26 trading update delivered a meaningful acceleration in Australian comp sales growth, providing tangible evidence that the business is executing well against a challenging consumer backdrop. Transaction growth continued to outpace comp sales growth, maintaining GYG’s strategy to be volume and frequency-led rather than price-driven. We have upgraded our comp sales growth assumptions and lifted our price target to A$26.70, reflecting higher forecast earnings and an increase in our valuation multiple to 24x FY27 EV/EBITDA. We maintain our BUY rating.

SOL has recently released its 1H26 result, which represents the first reporting period post the completion of the Brickworks (BKW) merger (Sep-25). It was another strong period for SOL, with Pre-tax NAV increasing ~15% on pcp to ~A$13.8bn. The portfolio delivered a 9.7% increase in NAV per share in the period (versus the ASX200 total return index returning 3.1%). Net cash flow from investments (NCFI) grew ~15% on pcp to ~A$334m, supported by strong contributions from the private, credit and real asset portfolios. Regular NPAT from the portfolio was up ~21% on pcp to ~A$397m. A 48cps fully-franked interim dividend was declared (28 consecutive years of dividend increases). Our DDM/SOTP-derived price target is now A$41.85 following the BKW merger, which materially changed the portfolio composition and tax base. We also remove the associated premium we had applied to our prior valuation to factor in index upweighting post the merger. Our updated forecasts are overleaf. We continue to like the SOL story, particularly its track record of growing distributions and history of uncorrelated and above market returns. We maintain our Hold recommendation.